BioCentury
ARTICLE | Financial News

Dimension raises $65M in series B

April 22, 2015 2:19 AM UTC

Dimension Therapeutics Inc. (Cambridge, Mass.) raised $65 million in a series B round led by new investor New Leaf Venture Partners. Other new investors included Jennison Associates; Partner Fund Management; RA Capital; Rock Springs Capital; Tourbillon Global Ventures, and an undisclosed life sciences investor. Existing investors Fidelity Biosciences and OrbiMed also participated.

Dimension is developing gene therapies for rare diseases using its adeno-associated virus (AAV) platform. The company plans to start a clinical trial in 2H15 of its lead candidate, an as-yet-unnamed AAV delivering wild type factor IX, to treat hemophilia B. ...